Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) — Net Asset Quality Index
Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has a Net Asset Quality Index of 86.1% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.60 Billion minus total liabilities of CN¥222.24 Million yields net assets of CN¥1.38 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check asset resilience ratio of Shandong Keyuan Pharmaceutical Co. Ltd. to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shandong Keyuan Pharmaceutical Co. Ltd. A Net Asset Quality Index Over Time (2021–2024)
This chart shows how Shandong Keyuan Pharmaceutical Co. Ltd. A's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the index stands at 86.1%, representing net assets of CN¥1.38 Billion against total assets of CN¥1.60 Billion CNY. See Shandong Keyuan Pharmaceutical Co. Ltd. (301281) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shandong Keyuan Pharmaceutical Co. Ltd. market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 87.6% | CN¥1.36 Billion | CN¥1.55 Billion | CN¥192.87 Million | ▼ -3.0 pp |
| 2023 | 90.5% | CN¥1.33 Billion | CN¥1.47 Billion | CN¥138.93 Million | ▲ +10.8 pp |
| 2022 | 79.7% | CN¥519.73 Million | CN¥651.79 Million | CN¥132.06 Million | ▲ +2.7 pp |
| 2021 | 77.0% | CN¥430.98 Million | CN¥559.51 Million | CN¥128.52 Million | — |